Antithymocyte antiserum therapy in myasthenia gravis.
The therapeutic effect of goat anti-human thymocyte antiserum globulin (ATG) was assessed in 10 patients with myasthenia gravis. Prolonged, low dose therapy was used with 1-0--1-6 grams protein administered intramuscularly over a 28-73 day period. Varying degrees of therapeutic response were noted in 8 patients. Fllow-up examinations for over 5 years have been maintained and relapse rates determined. The clinical criteria for aptients selection and characteristics of therapeutic response are presented.
D000293:Adolescent; D000328:Adult; D000818:Animals; D000961:Antilymphocyte Serum / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006041:Goats / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000188:drug therapy*; D013601:T-Lymphocytes / Q000276:immunology*
D000961:Antilymphocyte Serum